<DOC>
	<DOCNO>NCT02951962</DOCNO>
	<brief_summary>This phase 1 , open label , two-cohort , single-sequence , crossover study</brief_summary>
	<brief_title>A Study Investigate Pharmacokinetic Drug Interaction Safety Telmisartan/Amlodipine Rosuvastatin</brief_title>
	<detailed_description>This phase 1 , open label , two-cohort , single-sequence , crossover study investigate pharmacokinetic drug interaction safety Telmisartan/Amlodipine Rosuvastatin healthy male volunteer .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Healthy male body mass index ( BMI ) 18.5 28 kg/m2 Who suffer clinically significant disease Provision sign write informed consent History clinically significant disease A history drug abuse presence positive reaction drug abuse potential urine screening drug Administration investigational product within 3 month prior first dose Volunteers consider eligible clinical trial investigator due reason include laboratory test result , ECGs , vital sign Sitting blood pressure meeting follow criterion screen : 160 ≥ systolic blood pressure ≤100 ( mmHg ) 95 ≥ diastolic blood pressure ≤ 60 ( mmHg )</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>